COVID-19 vaccines and kidney disease
Martin Windpessl, Annette Bruchfeld, Hans-Joachim Anders, Holly Kramer, Meryl Waldman, Laurent Renia, Lisa F P Ng, Zhou Xing, Andreas Kronbichler, Martin Windpessl, Annette Bruchfeld, Hans-Joachim Anders, Holly Kramer, Meryl Waldman, Laurent Renia, Lisa F P Ng, Zhou Xing, Andreas Kronbichler
Abstract
Patients with kidney diseases should be prioritized for COVID-19 vaccination and the available data suggest that replication-defective viral-vectored vaccines and mRNA vaccines are safe to use. As vaccine responses are likely to be lower in patients with kidney diseases than in the general population, highly potent vaccines should be preferred.
Conflict of interest statement
A.B. received grants and personal fees from AstraZeneca and personal fees from ChemoCentryx, Merck/MSD, Vifor and Abbvie, all unrelated to the context of this article. H.J.A. received honoraria from AstraZeneca, GSK, Bayer, Boehringer Ingelheim, Novartis, Previpharma, Inositec and Noxxon, all unrelated to the context of this article. A.K. received honoraria from Miltenyi Biotech, Vifor, TerumoBCT and Novartis, all unrelated to the context of this article.
References
- US National Library of Medicine. (2021).
- Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577.
- Baden LR, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 2020 doi: 10.1056/NEJMoa2035389.
- Voysey M, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. doi: 10.1016/S0140-6736(20)32661-1.
- Jeyanathan M, et al. Immunological considerations for COVID-19 vaccine strategies. Nat. Rev. Immunol. 2020;20:615–632. doi: 10.1038/s41577-020-00434-6.
- Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet. 2020;396:1595–1606. doi: 10.1016/S0140-6736(20)32137-1.
- Schmidt ME, Varga SM. The CD8 T cell response to respiratory virus infections. Front. Immunol. 2018;9:678. doi: 10.3389/fimmu.2018.00678.
- Labriola L, et al. A longitudinal, 3-month serologic assessment of SARS-CoV-2 infections in a Belgian hemodialysis facility. Clin. J. Am. Soc. Nephrol. 2020 doi: 10.2215/CJN.12490720.
- Baker D, et al. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clin. Exp. Immunol. 2020;202:149–161. doi: 10.1111/cei.13495.
- Scharpé J, et al. Influenza vaccination is efficacious and safe in renal transplant recipients. Am. J. Transplant. 2008;8:332–337. doi: 10.1111/j.1600-6143.2007.02066.x.
Source: PubMed